LRRC8A and cardiac hypertrophy: In 2021, a new study of our group further elucidated that in the angiotensin II-induced cardiac hypertrophy model, the VRAC’s core structural protein LRRC8A interacts with NADPH through its LRRD domain to participate in the regulation of cardiac hypertrophy, knockdown of LRRC8A-attenuated AngII-induced cardiomyocyte hypertrophy [28].